To further groups of five anaesthetized rats, different doses of the peptides formulated in the Axcess vehicle comprising a mixture of 50 mg sodium chenodeoxycholate and propyl gallate (2:1 wt:wt) were dissolved in water and instilled by injection directly into the intestinal lumen of the anaesthetised rats using an insulin syringe with a 30 gauge needle (t = 0 min)
These drugs mimic a hormone in the body called glucagon-like peptide-1 (GLP-1)
The Key Takeaways: Most common: Nausea (43%), manageable with dietary changes and timing Unique: Dysesthesia (20.9%), mild tingling sensations, not seen with Wegovy/Mounjaro Timeline: Worst during dose escalation (weeks 116), significant improvement after Discontinuation: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 the general obesity population tolerates it better than the osteoarthritis cohort Reversible: Stopping medication reverses side effects For most people with obesity especially severe obesity the 28.328.7% weight loss and associated health benefits outweigh the temporary discomfort during the first few months
In particular, the antidepressants fluoxetine (Prozac and Sarafem) and paroxetine have the ability to greatly reduce the effectiveness of tamoxifen as they are strong inhibitors of CYP2D6, therefore they should not be prescribed in conjunction with tamoxifen
Who can benefit from taking this supplement
Adaptive strategies of the candidate probiotic E
